Completing the clinical development and introduction of a unique oral modified-release capsule formulation of budesonide, Nefecon, for an orphan indication, the inflammatory renal disease, IgA nephropathy, is the aim of a proposed initial public offering (IPO) and listing of the Swedish specialty company, Calliditas Therapeutics AB (previously known as Pharmalink AB), on Nasdaq Sweden.
The company, which is based in Stockholm, Sweden, will use the funding proceeds to support a pivotal global Phase III study, NEFIGARD, expected to start patient recruitment in the second half of 2018
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?